/CCCC
CCCC Stock - C4 Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$2.03+1.00%
+$0.02 (+1.00%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.34
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.5
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+310.3%upside
Target: $8.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CCCC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.01 – $2.05
TARGET (TP)$8.33
STOP LOSS$1.87
RISK/REWARD1:39.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.89
52W High$4.26
52W Low$1.08
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $35.58M | $20.76M | $31.10M | $45.78M | $33.20M |
| Gross Profit | $35.58M | $13.02M | $31.10M | $45.78M | $-45,245,000 |
| Gross Margin | 100.0% | 62.7% | 100.0% | 100.0% | -136.3% |
| Operating Income | $-119,614,000 | $-139,031,000 | $-129,534,000 | $-82,134,000 | $-60,449,000 |
| Net Income | $-105,316,000 | $-132,493,000 | $-128,175,000 | $-83,892,000 | $-66,334,999 |
| Net Margin | -296.0% | -638.3% | -412.2% | -183.2% | -199.8% |
| EPS | $-1.52 | $-2.67 | $-2.62 | $-1.82 | $-1.54 |
Company Overview
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
33%
Hold / Neutral
5
56%
Sell / Underperform
1
11%
Analyst Consensus🔴 Bearish
3 Bullish6 Neutral/Bearish
Price Targets
$9
Average Target
↑ 343.3% Upside
Now
$4
Low
$9
Average
$15
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | TD Cowen | Initiation | Buy | - |
| September 17th 2025 | Barclays | Initiation | Overweight | $8 |
| September 15th 2025 | Stephens | Upgrade | Overweight | $6 |
| September 4th 2025 | Guggenheim | Initiation | Buy | $8 |
| December 19th 2024 | Wells Fargo | Upgrade | Overweight | $12← $8 |
| November 18th 2024 | Stephens | Initiation | Equal Weight | $4 |
| January 29th 2024 | JP Morgan | Upgrade | Neutral | $6 |
| December 13th 2023 | Stifel | Upgrade | Buy | $12← $2 |
| February 24th 2023 | Credit Suisse | Upgrade | Neutral | $10← $12 |
| February 24th 2023 | JP Morgan | Downgrade | Underweight | $5← $15 |
| November 4th 2022 | JP Morgan | Downgrade | Neutral | $15← $22 |
| October 11th 2022 | Morgan Stanley | Initiation | Underweight | $6 |
| April 28th 2022 | Credit Suisse | Initiation | Underperform | $10 |
| April 11th 2022 | BofA Securities | Downgrade | Neutral | $15← $46 |
Earnings History & Surprises
CCCCBeat Rate
67%
Last 18 quarters
Avg Surprise
+9.4%
EPS vs Estimate
Beats / Misses
12/4
2 met exactly
Latest EPS
$-0.44
Q4 2025
EPS Surprise History
Q1 24
-1.5%
$-0.68vs$-0.67
Q2 24
0.0%
$-0.41vs$-0.41
Q3 24
+29.7%
$-0.26vs$-0.37
Q4 24
+12.5%
$-0.35vs$-0.40
Q1 25
-11.4%
$-0.49vs$-0.44
Q2 25
+22.9%
$-0.37vs$-0.48
Q3 25
+2.6%
$-0.37vs$-0.38
Q4 25
+6.4%
$-0.44vs$-0.47
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.43 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.47 | $-0.44 | +6.4% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.38 | $-0.37 | +2.6% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.48 | $-0.37 | +22.9% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.44 | $-0.49 | -11.4% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $-0.40 | $-0.35 | +12.5% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-0.37 | $-0.26 | +29.7% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.41 | $-0.41 | 0.0% | = MET |
Q1 2024 | Feb 22, 2024 | $-0.67 | $-0.68 | -1.5% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.65 | $-0.55 | +15.4% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.74 | $-0.73 | +1.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.78 | $-0.71 | +9.0% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.72 | $-0.76 | -5.6% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.65 | $-0.65 | 0.0% | = MET |
Q3 2022 | Aug 4, 2022 | $-0.68 | $-0.56 | +17.6% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.61 | $-0.65 | -6.6% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.59 | $-0.31 | +47.5% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.60 | $-0.51 | +15.0% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.60 | $-0.51 | +15.0% | ✓ BEAT |
Latest News
Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5
➖ NeutralBenzinga•Dec 17, 2025, 05:36 PM•Also:
TD Cowen Initiates Coverage On C4 Therapeutics with Buy Rating
📈 PositiveBenzinga•Dec 2, 2025, 12:20 PM
C4 Therapeutics Files For Mixed Shelf Of Up To $400M
➖ NeutralBenzinga•Nov 21, 2025, 09:08 PM
C4 Therapeutics Q3 EPS $(0.44) Misses $(0.40) Estimate, Sales $11.230M Beat $6.280M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 12:10 PM
C4 Therapeutics 13G Filing Shows Point72 Asset Management LP Reports 9.9% Passive Stake In Co As Of Oct 17, 2025
📈 PositiveBenzinga•Oct 20, 2025, 10:19 PM
C4 Therapeutics Priced An Underwritten Offering To Institutional Investors For 21.9M Shares Of Common Stock And Pre-funded Warrants For Up To 28.7M Additional Shares
➖ NeutralBenzinga•Oct 16, 2025, 11:10 AM
C4 Therapeutics Announces Clinical Trial Collaboration And Supply Agreement With Pfizer; Pfizer To Supply Elranatamab To C4 Therapeutics For Its Upcoming Phase 1b Trial In Relapsed/Refractory Multiple Myeloma
📈 PositiveBenzinga•Oct 1, 2025, 11:03 AM•Also:
Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10
📈 PositiveBenzinga•Sep 23, 2025, 12:43 PM
Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target
📈 PositiveBenzinga•Sep 22, 2025, 12:22 PM
Reported Saturday, C4 Therapeutics Reports Phase 1 Cemsidomide Data Showing 50% Response Rate In Relapsed Refractory Multiple Myeloma At International Myeloma Society Meeting
📈 PositiveBenzinga•Sep 22, 2025, 06:54 AM
Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8
📈 PositiveBenzinga•Sep 17, 2025, 10:49 AM•Also:
C4 Therapeutics shares are trading higher after Stephens & Co upgraded the stock from Equal-Weight to Overweight and raised its price target from $3 to $6.
📈 PositiveBenzinga•Sep 15, 2025, 03:46 PM
Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6
📈 PositiveBenzinga•Sep 15, 2025, 01:39 PM
Guggenheim Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $8
📈 PositiveBenzinga•Sep 4, 2025, 02:03 PM
C4 Therapeutics Highlights Biogen Collaboration Milestone As FDA Accepts IND For BIIB142, An IRAK4 Degrader Targeting Autoimmune Diseases
📈 PositiveBenzinga•Sep 4, 2025, 11:26 AM•Also:
Frequently Asked Questions about CCCC
What is CCCC's current stock price?
C4 Therapeutics, Inc. (CCCC) is currently trading at $2.03 per share. The stock has moved +1.00% today.
What is the analyst price target for CCCC?
The average analyst price target for CCCC is $8.33, based on 1 analyst.
What sector is C4 Therapeutics, Inc. in?
C4 Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CCCC's market cap?
C4 Therapeutics, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does CCCC pay dividends?
No, C4 Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.16
Mkt Cap: $0.2B
CDXS
Codexis, Inc.
$1.66
Mkt Cap: $0.1B
CYBN
Cybin Inc.
$7.18
Mkt Cap: $0.4B
IMDX
Insight Molecular Diagnostics Inc.
$5.41
Mkt Cap: $0.2B
MIST
Milestone Pharmaceuticals Inc.
$2.15
Mkt Cap: $0.2B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
OABI
OmniAb, Inc.
$2.09
Mkt Cap: $0.2B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
SAVA
Cassava Sciences, Inc.
$2.17
Mkt Cap: $0.1B
SGMO
Sangamo Therapeutics, Inc.
$0.45
Mkt Cap: $0.2B
Explore stocks similar to CCCC for comparison